Last update 19 Jun 2024

SAR-440234

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
SAR 440234, SAR440234
Target
CD123 x CD3
Mechanism
CD123 modulators(Interleukin-3 receptor subunit alpha modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Acute Myeloid LeukemiaLymphoid LeukemiaMyelodysplastic Syndromes
Inactive Indication
High Risk Myelodysplastic SyndromePre B-cell acute lymphoblastic leukemiaRefractory acute myeloid leukemia
Originator Organization
SanofiSanofi
Active Organization
SanofiSanofi
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Related

1
Clinical Trials associated with SAR-440234
NCT03594955 / TerminatedPhase 1/2
An Open-label, First-in-human, Dose Escalation Study of SAR440234 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), or High Risk Myelodysplasia (HR-MDS)
100 Clinical Results associated with SAR-440234
Login to view more data
100 Translational Medicine associated with SAR-440234
Login to view more data
100 Patents (Medical) associated with SAR-440234
Login to view more data
100 Deals associated with SAR-440234
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk Myelodysplastic SyndromePhase 2
US
Sanofi
24 Oct 2018
High Risk Myelodysplastic SyndromePhase 2
FR
Sanofi
24 Oct 2018
LeukemiaPhase 2
US
Sanofi
24 Oct 2018
LeukemiaPhase 2
FR
Sanofi
24 Oct 2018
Pre B-cell acute lymphoblastic leukemiaPhase 2
US
Sanofi
24 Oct 2018
Pre B-cell acute lymphoblastic leukemiaPhase 2
FR
Sanofi
24 Oct 2018
Refractory acute myeloid leukemiaPhase 2
US
Sanofi
24 Oct 2018
Refractory acute myeloid leukemiaPhase 2
FR
Sanofi
24 Oct 2018
Acute Myeloid LeukemiaPhase 2-
Sanofi
-
Lymphoid LeukemiaPhase 2-
Sanofi
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03594955 (CTgov)
Phase 1/2
High Risk Myelodysplastic Syndrome | Pre B-cell acute lymphoblastic leukemia | Refractory acute myeloid leukemia
7
mkvbnvqjil(yvtpprvjlp) = xanmuhzbur rwgznoulds (bbhppumbnb, lropanxivf - vcwtoxxwup)
View more
-
07 Apr 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free